Effectiveness of Personalized Therapy in Elderly Patients with Isolated Systolic Hypertension

E. A. Kartashova¹, PhD; Irina V. Sarvilina² , PhD, ScD

¹Rostov-on-Don State Medical University, Rostov-on-Don, Russian Federation; ²Medical Centre "Novomeditsina", Rostov-on-Don, Russian Federation

*Corresponding author: Irina V. Sarvilina, PhD, ScD. CEO of Medical Centre «Novomeditsina»; Rostov-on-Don, Russian Federation..E-mail: isarvilina@mail.ru

Published: December 3, 2015. DOI: 10.21103/Article5(4)_OA7


The purpose of this study was the development of personalized modes of therapy in elderly patients with isolated systolic hypertension (ISH).The study included 306 persons divided into two groups: Group 1(Control) included 150 elderly persons without arterial hypertension (AH), and Group 2 included 256 elderly patients (early old-age pension, between 65 and 74 years) with ISH (ESH/ESC,2013)  according to the inclusion/exclusion criteria. All patients of Group 2 were divided into three subgroups depending on the combination of drugs at the beginning of the study. Group 2a (n=53) received amlodipine (5mg/day) and indapamide-retard (1.5 mg/day), Group 2b (n=53) received valsartan (80 mg/day) and indapamide-retard (1.5 vg/day), and Group2c (n=50) received amlodipine (5 mg/day)  and valsartan (80 mg/day). The duration of therapy was 5.2 years. At the stage of data collection and screening, we applied standard methods for identification of ISH and secondary hypertension. Molecular phenotyping of blood serum was performed with methods of proteomics. We obtained the data of the molecular interactions and functional features of proteins from the STRING 10.0 database. Proteomic analysis contributes to the development of a personalized mode treatment in ISH patients, which is the safest and most efficient: 135 ISH patients switched to the administration of the amlodipine+valsartan combination.

isolated systolic hypertension; personalized therapy; proteomics, bioinformatics; molecular interactions.
  1. Nielsen WB, Vestbo J, Jensen GB. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens. 1995; 9(3):175-80.
  2. Boutouyrie P, Tropeano A, Asmar R, Gautier I, Benetos A, Lacolley P, at al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002.  39(1):10-5.
  3. McEniery CM1, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR.  Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005; 46(9):1753-1760.
  4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.

The fully formatted PDF version is available.      

Download Article

Int J Biomed. 2015; 5(4):203-206. © 2015 International Medical Research and Development Corporation. All rights reserved.